D
Theravance Biopharma, Inc.
TBPH
$8.45
-$0.32-3.65%
D
Sell
11/15/2024Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 11/15/2024 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 4.04% from $240.35M to $230.64M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 11/15/2024 due to a significant decline in the efficiency index, total return index and volatility index. Total capital declined 4.04% from $240.35M to $230.64M.
D
Sell
8/15/2024Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 8/15/2024 due to a decline in the total return index and volatility index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 8/15/2024 due to a decline in the total return index and volatility index.
D
Sell
8/5/2024Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 8/5/2024 due to a large increase in the efficiency index, volatility index and total return index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 8/5/2024 due to a large increase in the efficiency index, volatility index and total return index.
D
Sell
11/10/2023Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 11/10/2023 due to a significant decline in the valuation index, growth index and efficiency index. Total capital declined 10.51% from $331.84M to $296.96M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 11/10/2023 due to a significant decline in the valuation index, growth index and efficiency index. Total capital declined 10.51% from $331.84M to $296.96M.
D
Sell
8/10/2023Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 8/10/2023 due to a substantial increase in the growth index and efficiency index. EBIT increased 35.92% from -$23.34M to -$14.95M, total revenue increased 31.99% from $10.42M to $13.75M, and net income increased 29.17% from -$22.09M to -$15.65M.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 8/10/2023 due to a substantial increase in the growth index and efficiency index. EBIT increased 35.92% from -$23.34M to -$14.95M, total revenue increased 31.99% from $10.42M to $13.75M, and net income increased 29.17% from -$22.09M to -$15.65M.
D
Sell
6/26/2023Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 6/26/2023 due to a decline in the total return index and volatility index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 6/26/2023 due to a decline in the total return index and volatility index.
D
Sell
6/2/2023Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 6/2/2023 due to an increase in the volatility index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 6/2/2023 due to an increase in the volatility index.
D
Sell
5/18/2023Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 5/18/2023 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from -$0.1538 to -$0.351, net income declined 113.16% from -$10.36M to -$22.09M, and EBIT declined 45.68% from -$16.02M to -$23.34M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 5/18/2023 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from -$0.1538 to -$0.351, net income declined 113.16% from -$10.36M to -$22.09M, and EBIT declined 45.68% from -$16.02M to -$23.34M.
D
Sell
4/13/2023Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 4/13/2023 due to an increase in the volatility index and total return index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 4/13/2023 due to an increase in the volatility index and total return index.
D
Sell
3/2/2023Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 3/2/2023 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from $12.1384 to -$0.1538, and EBIT declined 16.99% from -$13.69M to -$16.02M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 3/2/2023 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from $12.1384 to -$0.1538, and EBIT declined 16.99% from -$13.69M to -$16.02M.
D
Sell
2/1/2023Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D+ from C- on 2/1/2023 due to a decline in the total return index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D+ from C- on 2/1/2023 due to a decline in the total return index.
C
Hold
12/14/2022Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to C- from D+ on 12/14/2022 due to an increase in the total return index and volatility index.
Theravance Biopharma, Inc. (TBPH) was upgraded to C- from D+ on 12/14/2022 due to an increase in the total return index and volatility index.
D
Sell
11/29/2022Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D+ from C- on 11/29/2022 due to a decline in the volatility index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D+ from C- on 11/29/2022 due to a decline in the volatility index.
C
Hold
11/10/2022Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to C- from D on 11/10/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 11,290.71% from -$8.19M to $916.63M, and total capital increased 62.32% from $328.15M to $532.65M.
Theravance Biopharma, Inc. (TBPH) was upgraded to C- from D on 11/10/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 11,290.71% from -$8.19M to $916.63M, and total capital increased 62.32% from $328.15M to $532.65M.
D
Sell
5/31/2022Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and valuation index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index and valuation index.
D
Sell
5/13/2022Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, volatility index and total return index. Total revenue declined 11.71% from $14.95M to $13.2M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, volatility index and total return index. Total revenue declined 11.71% from $14.95M to $13.2M.
D
Sell
5/5/2022Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and total return index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
11/9/2021Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from E+ on 11/09/2021.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index and volatility index.
Theravance Biopharma, Inc. (TBPH) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index and volatility index.
D
Sell
6/10/2020Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 6/10/2020 due to a decline in the volatility index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 6/10/2020 due to a decline in the volatility index.
D
Sell
5/26/2020Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 5/26/2020 due to an increase in the total return index and growth index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 5/26/2020 due to an increase in the total return index and growth index.
D
Sell
5/11/2020Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 5/11/2020 due to a decline in the growth index. Total revenue declined 32.67% from $29.5M to $19.86M, earnings per share declined from -$1.1694 to -$1.3967, and EBIT declined 2.7% from -$70.57M to -$72.48M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D from D+ on 5/11/2020 due to a decline in the growth index. Total revenue declined 32.67% from $29.5M to $19.86M, earnings per share declined from -$1.1694 to -$1.3967, and EBIT declined 2.7% from -$70.57M to -$72.48M.
D
Sell
5/8/2020Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 137.38% from $12.43M to $29.5M.
Theravance Biopharma, Inc. (TBPH) was upgraded to D+ from D on 5/8/2020 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 137.38% from $12.43M to $29.5M.
D
Sell
1/29/2020Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 1/29/2020 due to an increase in the volatility index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 1/29/2020 due to an increase in the volatility index.
D
Sell
3/29/2019Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, volatility index and valuation index.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 3/29/2019 due to a decline in the total return index, volatility index and valuation index.
D
Sell
11/14/2018Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 11/14/2018 due to an increase in the valuation index and volatility index.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 11/14/2018 due to an increase in the valuation index and volatility index.
D
Sell
5/12/2017Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 5/12/2017 due to a decline in the solvency index, efficiency index and valuation index. The quick ratio declined from 10.37 to 8.2, debt to equity increased from 0.64 to 0.76, and total capital declined 9.78% from $572.91M to $516.89M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 5/12/2017 due to a decline in the solvency index, efficiency index and valuation index. The quick ratio declined from 10.37 to 8.2, debt to equity increased from 0.64 to 0.76, and total capital declined 9.78% from $572.91M to $516.89M.
D
Sell
3/3/2017Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 3/3/2017 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 92.33% from $297.87M to $572.91M.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 3/3/2017 due to an increase in the total return index, efficiency index and volatility index. Total capital increased 92.33% from $297.87M to $572.91M.
D
Sell
8/10/2016Downgrade
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 8/10/2016 due to a decline in the solvency index, efficiency index and volatility index. Net income declined 12.04% from -$42.15M to -$47.23M.
Theravance Biopharma, Inc. (TBPH) was downgraded to D- from D on 8/10/2016 due to a decline in the solvency index, efficiency index and volatility index. Net income declined 12.04% from -$42.15M to -$47.23M.
D
Sell
6/1/2015Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 6/1/2015 due to an increase in the solvency index and volatility index. The quick ratio increased from 6.22 to 8.89.
Theravance Biopharma, Inc. (TBPH) was upgraded to D from D- on 6/1/2015 due to an increase in the solvency index and volatility index. The quick ratio increased from 6.22 to 8.89.
D
Sell
2/2/2015Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to D- from E+ on 2/2/2015 due to an increase in the growth index and valuation index. Total revenue increased 113.05% from $2.97M to $6.34M.
Theravance Biopharma, Inc. (TBPH) was upgraded to D- from E+ on 2/2/2015 due to an increase in the growth index and valuation index. Total revenue increased 113.05% from $2.97M to $6.34M.
E
Sell
11/3/2014Upgraded
Theravance Biopharma, Inc. (TBPH) was upgraded to E+ from E on 11/3/2014 due to a significant increase in the solvency index, total return index and growth index. The quick ratio increased from 0 to 9.09, total revenue increased 214.71% from $945 to $2.97M, and operating cash flow increased 14.82% from -$44.8M to -$51.44M.
Theravance Biopharma, Inc. (TBPH) was upgraded to E+ from E on 11/3/2014 due to a significant increase in the solvency index, total return index and growth index. The quick ratio increased from 0 to 9.09, total revenue increased 214.71% from $945 to $2.97M, and operating cash flow increased 14.82% from -$44.8M to -$51.44M.
E
Sell
8/11/2014None
Theravance Biopharma, Inc. (TBPH) was downgraded to E from U on 08/11/2014.
Theravance Biopharma, Inc. (TBPH) was downgraded to E from U on 08/11/2014.
NASDAQ
04/04/2025 12:56PM Eastern
Quotes delayed
